comparemela.com

Latest Breaking News On - Krankenhaus nordwest - Page 1 : comparemela.com

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

Media ReleaseSYDNEY, AUSTRALIA, Jan. 04, 2024 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep” or “the Company”), a clini.

United statesNew south walesKrankenhaus nordwestChris bastaDrug administrationImmutep limitedUs national cancer instituteMerck kgaaInstitute of clinical cancer researchCorporate communicationsMerck kgaClinical cancer researchHelios klinikum bad saarowDaniel pinkEftilagimod alphaFast track

Imfinzi-Chemo Combo Shows Promise in Ongoing Gastric Cancer Trial

The addition of Imfinzi to a chemotherapy regimen called FLOT tended to boost pathologic complete response rates in patients with gastric or gastroesophageal junction cancer.

Krankenhaus nordwestSalah eddin al batranUniversity cancer centerInstitute of clinical cancer researchClinical cancer researchGastrointestinal oncologyKrankenhaus nordwest university cancer centerGastric cancer

Duvalumab Plus Chemotherapy Elicits pCR Improvement in Resectable Gastric/GEJ Cancer

The addition of durvalumab to 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel produced statistically significant and clinically meaningful improvements in pathological complete response rates vs placebo plus FLOT in patients with resectable gastric cancer or gastroesophageal junction cancer.

Krankenhaus nordwestSalah eddin al batranInstitute of clinical cancer researchUniversity cancer centerClinical cancer researchGastrointestinal oncologyKrankenhaus nordwest university cancer centerEsmo congressGej cancer

Immutep Announces Publication of Abstracts at ESMO Congress 2023

Media ReleaseNew updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Satur.

New south walesUnited statesEnric carcerenyChris bastaFlorian voglKatarzyna kozakChristian muellerFrederic triebelMarc voigtKrankenhaus nordwestCatalan institute of oncologyMerck co incStrategic developmentImmutep limitedCurie national research institute of oncologyCorporate communications

Hygrovest Ltd welcomes dosing of first patient by investment ValoTx in Phase I trial

Hygrovest Ltd (ASX:HGV, OTC:MMJJF) welcomes the dosing by its Finland-based investment Valo Therapeutics Oy (ValoTx) of the first patient in a Phase I trial.

Baden wübergEteläuomen läiPaul highamKrankenhaus nordwestVincenzo cerulloUniversity of helsinkiHygrovest ltdSafety data committeeNational centerProfessor vincenzo cerulloTumor diseasesProf guy ungerechts

vimarsana © 2020. All Rights Reserved.